RFA-AG-25-022: Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD (R01 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2024.
National Institutes of Health offered grants of up to $125,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on November 1, 2024.
From the official notice on Grants.gov, last changed July 31, 2024. Checked November 7, 2026.
- Award ceiling$125,000
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR01
- Clinical trialsNot allowed
- Funded byNIA
- Median yearly award$806,588
- Typical project length4.5 years
- R01, Research Project Grant. NIH's standard grant for a defined research project led by a named investigator, usually for up to five years. Other open R01 notices.
Projects funded under RFA-AG-25-022 were run by National Institute on Aging (NIA, 7 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-AG-25-022 in the NIH Guide.
Key dates
| Posted | July 31, 2024 |
|---|---|
| Deadline | November 1, 2024 |
| Archived by Grants.gov | December 7, 2024 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $806,588; it allows up to $125,000 per award.
- Most of the program's money (73% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this Notice of Funding Opportunity (NOFO) is to catalyze innovative research to elucidate the molecular landscape and functional implications of RNA modifications in brain aging and Alzheimer's disease (AD) and AD-related dementias (ADRD). AD-related dementias include Lewy body dementia (LBD), frontotemporal dementia (FTD), vascular cognitive impairment/dementia (VCI/D), and mixed dementias. This NOFO supports applications focused on uncovering novel mechanisms underlying RNA modification-mediated processes and their impact on brain aging and the pathogenesis and progression of AD/ADRD. The ultimate goal is to identify targets for biomarker discovery and drug development for AD/ADRD.
Funded under RFA-AG-25-022 so far
NIH funded 7 projects under RFA-AG-25-022 in fiscal 2025 to 2026, at 7 institutions. The median yearly award was $806,588.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| RNA modifications leading to pathophysiological translation of circRNAs in AD | University of Kentucky | 2026 | $595,769 |
| Role of m6A RNA Modifications in Microglial Dysfunction and Alzheimer's Disease Pathogenesis | Icahn School of Medicine at Mount Sinai | 2026 | $839,933 |
| tRNA Epitranscriptome and Translational Dysfunction in ADRD | Boston University Medical Campus | 2026 | $801,569 |
| Transcriptome-wide mapping of brain m6A methylome in Alzheimer’s disease | University of South Florida | 2026 | $786,683 |
| Impact of m6A RNA modifications in Alzheimer's disease and tauopathies | University of California, San Francisco | 2026 | $807,603 |
| Epitranscriptomic Regulation of Microglia in Alzheimer's Disease | Duke University | 2026 | $578,858 |
| Genetic Mapping of m6A and Pseudouridine RNA Modifications in the Aging Human Brain and Their Impact on Alzheimer's Disease | Columbia University Health Sciences | 2026 | $820,023 |
Who has won Aging Research grants before
From fiscal 2021 to 2025, Aging Research (93.866) awarded $19 billion across 11,026 grant awards, an average of $1.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Regents of the University of California, San Francisco | California | 337 | $575 million |
| The Trustees of Columbia University in the City of New York | New York | 242 | $574 million |
| University of Southern California | California | 203 | $572 million |
| The Washington University | Missouri | 210 | $556 million |
| Regents of the University of Michigan | Michigan | 232 | $538 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-AG-25-022 still open?
No. It closed on November 1, 2024.
Who can apply for Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD (R01 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD (R01 Clinical Trial Not Allowed)?
Closed November 1, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $125,000 each.
Who has been funded under RFA-AG-25-022?
NIH RePORTER lists 7 projects funded under RFA-AG-25-022 in fiscal 2025 to 2026, at 7 institutions. The most were at University of Kentucky, Icahn School of Medicine at Mount Sinai, Boston University Medical Campus.
Who has won Aging Research grants before?
The largest recipients over five fiscal years were The Regents of the University of California, San Francisco, The Trustees of Columbia University in the City of New York, University of Southern California. The program made 11,026 awards worth $19 billion in that time.
Similar open grants
- NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
- NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)
- Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)
- Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)
- Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
- Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)